Literature DB >> 17671156

The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.

Jeffrey A Engelman1.   

Abstract

The phosphoinositide 3-kinase signaling network is widely implicated in the pathogenesis of human cancer. This pathway is commandeered by cancer cells to promote unrestrained cellular growth and survival. In this brief review, we speculate about the uses of inhibitors of phosphoinositide 3-kinase signaling as treatments for human cancers, with an emphasis on non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671156     DOI: 10.1158/1078-0432.CCR-07-0653

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Development of rational drug combinations with investigational targeted agents.

Authors:  Adam Clark; Matthew Ellis; Charles Erlichman; Stuart Lutzker; James Zwiebel
Journal:  Oncologist       Date:  2010

2.  Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.

Authors:  Jingchun Gao; Zhong Zheng; Bhupendra Rawal; Michael J Schell; Gerold Bepler; Eric B Haura
Journal:  Cancer Biol Ther       Date:  2009-09-20       Impact factor: 4.742

3.  CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.

Authors:  Jeffrey H Becker; Yandi Gao; Margaret Soucheray; Ines Pulido; Eiki Kikuchi; María L Rodríguez; Rutu Gandhi; Aranzazu Lafuente-Sanchis; Miguel Aupí; Javier Alcácer Fernández-Coronado; Paloma Martín-Martorell; Antonio Cremades; José M Galbis-Caravajal; Javier Alcácer; Camilla L Christensen; Patricia Simms; Ashley Hess; Hajime Asahina; Michael P Kahle; Fatima Al-Shahrour; Jeffrey A Borgia; Agustín Lahoz; Amelia Insa; Oscar Juan; Pasi A Jänne; Kwok-Kin Wong; Julian Carretero; Takeshi Shimamura
Journal:  Cancer Res       Date:  2019-07-04       Impact factor: 12.701

4.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

Authors:  Marta Guix; Anthony C Faber; Shizhen Emily Wang; Maria Graciela Olivares; Youngchul Song; Sherman Qu; Cammie Rinehart; Brenda Seidel; Douglas Yee; Carlos L Arteaga; Jeffrey A Engelman
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

5.  Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis.

Authors:  Asawari Korde; Lei Jin; Jian-Ge Zhang; Anuradha Ramaswamy; Buqu Hu; Saeed Kolahian; Brenda Juan Guardela; Jose Herazo-Maya; Jill M Siegfried; Laura Stabile; Margaret A Pisani; Roy S Herbst; Naftali Kaminski; Jack A Elias; Jonathan T Puchalski; Shervin S Takyar
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

Review 6.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

7.  The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Authors:  Tanguy Y Seiwert; Ramasamy Jagadeeswaran; Leonardo Faoro; Varalakshmi Janamanchi; Vidya Nallasura; Mohamed El Dinali; Soheil Yala; Rajani Kanteti; Ezra E W Cohen; Mark W Lingen; Leslie Martin; Soundararajan Krishnaswamy; Andres Klein-Szanto; James G Christensen; Everett E Vokes; Ravi Salgia
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

Review 8.  Role of miRNA let-7 and its major targets in prostate cancer.

Authors:  Siegfried Wagner; Anaclet Ngezahayo; Hugo Murua Escobar; Ingo Nolte
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

9.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

10.  Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.

Authors:  Xiaobing Deng; Jing Hu; Daina Z Ewton; Eileen Friedman
Journal:  Carcinogenesis       Date:  2014-03-03       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.